

## TQ Therapeutics participates in European consortium to decentralize CAR-T cell therapy and improve hospital workflows

*Martinsried, Germany, 26<sup>th</sup> August 2025* – TQ Therapeutics is contributing their proprietary cell selection technology to the €8 million EU-backed effort to make CAR-T cell therapy faster, more affordable, and more accessible to patients across Europe. The newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will develop a fully automated, hospital-based platform capable of manufacturing personalized cell therapies within 24 hours. The Innovative Health Initiative's (IHI) Call 7.2 targets user-centered technologies to relieve hospital staff and broaden access to advanced treatments. EASYGEN meets this goal by enabling rapid, in-hospital CAR-T cell production in days rather than weeks, accelerating patient access, reducing workloads, and lowering costs. EASYGEN leverages technology originally developed by Fresenius Kabi's Cell and Gene Therapy team.

CAR-T therapy is a breakthrough cancer treatment, yet fewer than 20% of eligible patients currently receive it. It involves genetically modifying a patient's T cells to target cancer, requiring complex, time-intensive production in specialized facilities often far from patients. Limited manufacturing capacity and supply chain delays prevent timely patient access.

TQx will contribute its proprietary, affinity- and column-based cell selection technology to the consortium, enabling the rapid and automated isolation of highly pure, untouched target cells from any starting material within just 30 to 45 minutes. By streamlining and accelerating the cell enrichment process, TQx's innovation paves the way for efficient, in-hospital CAR-T cell production, bringing advanced therapies closer to patients.

Dr. Christian Eckert, CEO of TQ Therapeutics states: *"We are thrilled to be part of the EASYGEN consortium, working alongside world-leading experts to revolutionize CAR-T therapies. Our proprietary T-cell selection technology will be a key component in optimizing point-of-care devices, helping to ensure that patients receive life-changing treatments precisely when and where they need them most."*

*"EASYGEN unites physicians, researchers, and partner institutions across Europe to collaboratively deliver innovative, personalized therapies more swiftly to where they matter most—to patients in need."* said Dr. Sonja Steppan, Head of Research Office/ Fresenius SE and Principal Investigator for EASYGEN. *"Automating patient-specific*

*therapies such as CAR-T is essential to make these treatments more broadly accessible, especially in non-academic clinical environments.”*

### **Consortium partners – 18 organizations across 8 countries**

**Industry & clinical leaders:** Fresenius SE & Co. KGaA (Coordinator) (DE), Helios Hospital Berlin-Buch (DE), QS Instituto (ES), Fenwal Inc. (US), Cellix Ltd. (IE), Charles River (DE), Pro-Liance Global Solutions (DE), TQ Therapeutics (DE), Philips Electronics Nederland B.V. (NL).

**Academic & research institutions:** Fraunhofer IESE (DE), Fraunhofer IZI (DE), Helmholtz-Zentrum Dresden-Rossendorf (DE), Technical University of Denmark (DK), Frankfurt School of Finance & Management (DE), European Society for Blood & Marrow Transplantation (SP), Bar-Ilan University (IL), University of Glasgow (UK), University of Navarra (ES).

### **About EASYGEN**

EASYGEN is a five-year research project supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194710. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and industry partners. Selected under the IHI call “*User-centric technologies and optimized hospital workflows for a sustainable healthcare workforce*”, the project aims to develop an integrated, automated platform that enables point-of-care CAR-T cell manufacturing—cutting production time, reducing costs, and expanding access to next-generation immunotherapies.

### **About TQ Therapeutics GmbH**

TQ Therapeutics is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company’s mission is to develop a transformative cell processing platform, enabling advanced and affordable treatments in CGT. This technology will deliver highly individualized cell therapies directly to the patient.

**Disclaimer:** Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.



## Contact

TQ Therapeutics GmbH

Christin Zündorf

Email: [info@tqtherapeutics.com](mailto:info@tqtherapeutics.com)

Web: <https://tqtherapeutics.com/>

LinkedIn: <https://www.linkedin.com/company/tq-therapeutics>




© Johannes Krzeslack

## Image Description (Left to Right)

In the front row, from left to right: Dr. Sonja Steppan (EASYGEN Principle Investigator, Fresenius SE), Prof. Dr. Michael Hudecek (Fraunhofer IZI), Theresa Kagerbauer (TQ Therapeutics), Dr. Agnes Vosen (HZDR), Christopher Wegener (Kabi), Vaclovas Radvilas (EBMT), Dr. Julia Schüler (Charles River), Dr. Julia Busch-Casler (HZDR), Nicole Spanier-Baro (Fraunhofer IESE), Vivienne Williams (Cellix Limited), Prof. Dr. Bertram Glaß (Helios), Prof. Dr. Ulrike Köhl (Fraunhofer IZI), Rebecca Scheiwe (Fresenius SE).

In the back row, from left to right: Prof. Dr. Ralf Kuhlen (Fresenius SE), Prof. Dr. Jens O. Brunner (DTU), Dominik Narres (Fresenius SE), Thomas Brzoska (Pro-Liance Global Solutions), Dr. David Krones (Fraunhofer IZI), Dr. Sabine Bertsch (Pro-Liance Global Solutions), Dr. Ralf Hoffmann (Philips), Christin Zündorf (TQ Therapeutics), Dr. Anna Dünkel (Fraunhofer IZI).





# easygen



## innovative health initiative

